![]() Biohaven Pharmaceutical Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system. | ![]() Shandong Saito Biotechnology Shandong Saito Biotechnology (山东斋藤生物科技) is a company that is engaged in the research and development and production of steroid drug intermediates. | ||||
Founding Date | Founding Date 1965 | Founding Date 2014 | Founding Date 1890 | Founding Date 1916 | Founding Date 2010 |
Type | Type Private | Type Subsidiary | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Karachi, PK HQ Karachi, PK Karachi, PK Lahore, PK | Locations New Haven, US HQ | Locations ID HQ | Locations Parkville, AU HQ King Of Prussia, US | Locations Heze, CN HQ |
Employees | Employees 2,3511% increase | Employees 4271% decrease | Employees 1,2341% increase | Employees 32,698 | Employees 1,200 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 95.1 b | Valuation ($) 708.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $14.7b (FY, 2024) | Revenue (est.) ¥1.2b (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $6.2b (FY, 2024) | Cost of goods ¥994.2m (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $8.6b (FY, 2024) | Gross profit ¥271.8m (FY, 2023) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income $2.7b (FY, 2024) | Net income ¥48.5m (FY, 2023) |
Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
View companyCSL is a biotech company providing life-saving medicines.
View companyShandong Saito Biotechnology (山东斋藤生物科技) is a company that is engaged in the research and development and production of steroid drug intermediates.
View company